Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jul 24;14(1):e12331.
doi: 10.1002/dad2.12331. eCollection 2022.

Development and implementation of an electronic Clinical Dementia Rating and Financial Capacity Instrument-Short Form

Taylor Howell  1   2 , Shilpa Gummadi  1   2 , Chau Bui  1   2 , Jessica Santhakumar  1   2 , Kristen Knight  1   2 , Erik D Roberson  3   4 , Daniel Marson  3   4 , Carol Chambless  3   4 , Adam Gersteneker  4 , Roy Martin  4 , Richard Kennedy  3   5 , Yue Zhang  5 , John C Morris  6 , Krista L Moulder  6 , Connie Mayo  6 , Maria Carroll  6 , Yan Li  6 , Ronald C Petersen  7 , Nikki H Stricker  8 , Rachel L Nosheny  2   9 , Scott Mackin  2   9 , Michael W Weiner  1   2
Affiliations

Development and implementation of an electronic Clinical Dementia Rating and Financial Capacity Instrument-Short Form

Taylor Howell et al. Alzheimers Dement (Amst). .

Abstract

Introduction: To address the need for remote assessments of cognitive decline and dementia, we developed and administered electronic versions of the Clinical Dementia Rating (CDR®) and the Financial Capacity Instrument-Short Form (FCI-SF) (F-CAP®), called the eCDR and eFCI, respectively.

Methods: The CDR and FCI-SF were adapted for remote, unsupervised, online use based on item response analysis of the standard instruments. Participants completed the eCDR and eFCI first in clinic, and then at home within 2 weeks.

Results: Of the 243 enrolled participants, 179 (73%) cognitively unimpaired (CU), 50 (21%) with mild cognitive impairment (MCI) or dementia, and 14 (6%) with an unknown diagnosis, 84% and 85% of them successfully completed the eCDR and eFCI, respectively, at home.

Discussion: These results show initial feasibility in developing and administering online instruments to remotely assess and monitor cognitive decline along the CU to MCI/very mild dementia continuum. Validation is an important next step.

Keywords: Alzheimer's disease; Brain Health Registry; aging research; internet; remote online instruments.

PubMed Disclaimer

Conflict of interest statement

Taylor Howell, Shilpa Gummadi, Chau Bui, Jessica Santhakumar, Kristen Knight, Carol Chambless, Adam Gersteneker, Roy Martin, Connie Mayo, Krista L. Moulder, Maria Carroll, and Yan Li have no interests to declare. Rachel L. Nosheny received support for her work from the NIH; received funding for academic travel from the Mild Cognitive Impairment (MCI) 2020 Symposium; and served on the International Society to Advance Alzheimer's Research and Treatment (ISTAART) Subjective Cognitive Decline (SCD) Professional Interest Area (PIA) “Dyadic Patterns of Subjective Report” workgroup. R. Scott Mackin has received research support from the National Institute of Mental Health and Johnson and Johnson. Nikki H. Stricker has received research support outside the scope of this work from the NIA, Alzheimer's Association, and Biogen; a Mayo Clinic invention disclosure has been submitted for remote cognitive assessment tools outside the scope of this work (the Stricker Learning Span and the Mayo Test Drive platform). Ronald C. Petersen receives funding from the National Institute on Aging: P30 AG062677, U01 AG006786, U01 AG024904, U24 AG057437 and National Institute for Neurological Disorders and Stroke: Uf1 NS125417. He consults for Roche, Inc., Merck, Inc, Biogen, Inc., Genentech, Inc., Eisai, Inc. and Nestle, Inc. He receives royalties from Oxford University Press and UpToDate. John C. Morris is funded by NIH grants # P30 AG066444; P01AG003991; P01AG026276; U19 AG032438; and U19 AG024904. Neither his nor his family owns stock or has equity interest (outside of mutual funds or other externally directed accounts) in any pharmaceutical or biotechnology company. Daniel Marson and UAB Research Foundation (UABRF) have previously received royalty income and other compensation for the use of the FCI‐SF in a clinical trial. He receives support from the NIH and is also the inventor of the FCI‐SF, which is owned by the UABRF. He and his company receive compensation for sales and services related to the FCI‐SF. He serves as a paid consultant to UCSD in connection to the e‐VAL research project and the present paper. Richard Kennedy and Yue Zhang receive support from NIH grants R01 AG057684 and R01AG059009. Erik D. Roberson receives support for his work from the following funding sources: NIH, Bluefield Project to Cure Frontotemporal Dementia, Alzheimer's Drug Discovery Foundation. He has also received support from the Alzheimer's Association, Alector, the Weston Brain Institute, and BrightFocus Foundation. He has served on advisory boards for Biogen, AGTC, and AVROBIO, and on a DSMB for Lilly. Michael W. Weiner receives support for his work from the following funding sources: NIH: 5U19AG024904‐14; 1R01AG053798‐01A1; R01 MH098062; U24 AG057437‐01; 1U2CA060426‐01; 1R01AG058676‐01A1; and 1RF1AG059009‐01, DOD: W81XWH‐15‐2‐0070; 0W81XWH‐12‐2‐0012; W81XWH‐14‐1‐0462; W81XWH‐13‐1‐0259, PCORI: PPRN‐1501‐26817, California Dept. of Public Health: 16–10054, U. Michigan: 18‐PAF01312, Siemens: 444951–54249, Biogen: 174552, Hillblom Foundation: 2015‐A‐011‐NET, Alzheimer's Association: BHR‐16‐459161; The State of California: 18–109929. He also receives support from Johnson & Johnson, Kevin and Connie Shanahan, GE, VUmc, Australian Catholic University (HBI‐BHR), The Stroke Foundation, and the Veterans Administration. He has served on Advisory Boards for Eli Lilly, Cerecin/Accera, Roche, Alzheon, Inc., Merck Sharp & Dohme Corp., Nestle/Nestec, PCORI/PPRN, Dolby Family Ventures, National Institute on Aging (NIA), Brain Health Registry and ADNI. He serves on the Editorial Boards for Alzheimer's & Dementia, TMRI, and MRI. He has provided consulting and/or acted as a speaker/lecturer to Cerecin/Accera, Inc., Alzheimer's Drug Discovery Foundation (ADDF), Merck, BioClinica, Eli Lilly, Indiana University, Howard University, Nestle/Nestec, Roche, Genentech, NIH, Lynch Group GLC, Health & Wellness Partners, Bionest Partners, American Academy of Neurology (AAN), NYU, Japanese Government Alliance, National Center for Geriatrics and Gerontology (Japan), US Against Alzheimer's, Society for Nuclear Medicine and Molecular Imaging (SNMMI), The Buck Institute for Research on Aging, FUJIFILM‐Toyama Chemical (Japan), Garfield Weston, Baird Equity Capital, and T3D Therapeutics. He holds stock options with Alzheon, Inc., Alzeca, and Anven. The following entities have provided funding for academic travel; Kenes, Intl., Merck, ADCS, ATRI, Eli Lilly, The Alzheimer's Association, Merck, Tokyo University, Kyoto University, AAN, AC Immune, CHU Toulouse, St. George Hospital University, Indiana U., U. Melbourne, Australian Catholic University, Japanese Government Alliance, National Center for Geriatrics and Gerontology (Japan), US Against Alzheimer's, NYU, USC, and SNMMI.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Grill JD, Karlawish J. Addressing the challenges to successful recruitment and retention in Alzheimer's disease clinical trials. Alzheimers Res Ther. 2010;2:34. 10.1186/alzrt58 - DOI - PMC - PubMed
    1. Cummings J, Aisen P, Barton R, et al. Re‐Engineering Alzheimer Clinical Trials: global Alzheimer's Platform Network. J Prev Alzheimers Dis. 2016;3:114–120. 10.14283/jpad.2016.93 - DOI - PMC - PubMed
    1. Pew Research Center. (2021, April 7).Demographics of Mobile Device Ownership and Adoption in the United States. Pew Research Center: Internet, Science & Tech. https://www.pewinternet.org/fact‐sheet/mobile/
    1. Wild K, Howieson D, Webbe F, Seelye A, Kaye J. Status of computerized cognitive testing in aging: a systematic review. Alzheimers Dement. 2008;4:428–437. 10.1016/j.jalz.2008.07.003 - DOI - PMC - PubMed
    1. Silverstein SM, Berten S, Olson P, et al. Development and validation of a World‐Wide‐Web‐based neurocognitive assessment battery: webNeuro. Behav Res Methods. 2007;39:940–949. 10.3758/BF03192989 - DOI - PubMed